OvaScience (OVAS) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
Leerink Partners Remains Sidelined on OvaScience (OVAS) Following 1Q
May 6, 2016 8:45 AM EDTLeerink Partners reiterated a Market Perform rating on OvaScience (NASDAQ: OVAS), and raised the price target to $7.00 (from $6.00), following the company's 1Q earnings report. OVAS reported EPS of ($0.80) which was below Leerink Partners' estimate of ($0.75). The weakness in EPS was due to higher than expected COGS and R&D... More
